MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Entrectinib (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Tucatinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms myTACTIC
- Sponsors Genentech
- 04 Jun 2024 Results (at data cut-off Jan 12, 2024, n=252) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 05 Mar 2024 Status changed from active, no longer recruiting to completed.
- 18 Dec 2023 Planned End Date changed from 28 Dec 2023 to 27 Feb 2024.